On 19 December 2016, the European Medicines Agency (“EMA”) published an updated version of the EMA guidance document concerning post-authorisation procedural advice for users of ...24 January 2017
PCORI Announces Cycle I Research Awards
- Assessing different prevention, diagnosis, and treatment options;
- Improving health care systems;
- Comparing approaches to communication and dissemination of CER information; and
- Addressing and potentially eliminating disparities across patient populations.
A PFA for proposals under PCORI’s fifth priority area, Accelerating Patient-Centered Outcomes Research and Methodological Research, was issued in November, with proposals due March 13, 2013. PCORI also plans to start issuing calls for proposals to study specific research topics in early 2013.
The awards were approved by PCORI’s Board of Governors through a competitive, multi-stage review process. Applications were evaluated on scientific merit, engagement of patients and other stakeholders, methodological rigor and fit within PCORI’s research priorities and research agenda. The projects approved for funding include those that will study ways to improve care for people with such health problems as bacterial and viral infections, cardiovascular disease and stroke, certain cancers, chronic kidney disease, chronic pain, depression and other serious mental illness, and pediatric diabetes, as well cross-cutting proposals investigating how to improve care for people with multiple conditions. Other projects seek ways to improve patient-clinician communication, reduce selected health disparities, and improve the way healthcare systems operate.
PCORI is an independent, non-profit organization created by Congress in the 2010 federal health reform law to fund CER that will enable patients, their caretakers, clinicians, and other system stakeholders to make more informed health care decisions.
Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (“the Clinical Trials Regulation”) was...24 January 2017
The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has published a draft strategy for developing pharmacopoeial public quality standards for biological...20 January 2017